Telix Pharmaceuticals has received FDA agreement on the protocol and [...]

Lonza will expand its highly potent active pharmaceutical ingredient manufacturing [...]

NICE has recommended cemiplimab for eligible adults with recurrent or [...]

InduPro has licensed Lonza’s antibody-drug conjugate technologies to support development [...]

The European Commission has approved BRAFTOVI in combination with cetuximab [...]

Lonza has entered an exclusive licensing agreement with Antharis Therapeutics [...]

Faeth Therapeutics has launched as a publicly traded oncology company [...]

Elicio Therapeutics has reported that its Phase 2 Amplify-7P trial [...]

Context Therapeutics has reported encouraging interim Phase 1 data for [...]

oryzon-iadademstat-aml-alice2-frida-eha-2026 Oryzon Genomics has reported updated Phase 1b data from [...]